Swedencare AB (publ) (SECARE) Q1 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Welcome to the presentation of SwedenCare's Q1 report, led by our CEO Håkan Lagerberg and CFO Jenny Graflind. And we are pleased to have our CEO of Europe, Laszlo Wege, joining us with a presentation during today's webinar. And as usual, we will have a Q&A after the presentations, so please raise your hand if you have any questions. Over to you, Jenny and Håkan. Thank you so much Emma. Warm welcome for our Q1 2026 presentation. We had a solid quarter starting the year good, double digit growth, improved gross margin compared to Q4 and 25 and increased profitability as we expected and communicated with our pre-call earlier this year. Margins and sales still impacted by Nature at Amazon project, the takeover. It is improving month by month. We target that the normalized levels will be in H2, 2026. The other issues we had in Q4 mitigated. And And we're happy that we could deliver that as we also communicated. Strong momentum, especially in Europe and production segments with 20% organic growth. And in different growth groups, pharma, we have been waiting for both development and manufacturing had a fantastic quarter. Dental, including Dental Month in the US predominantly, but it has been presented in Europe as well in some markets. Really strong demand for dental products and also online over all of our brands continue to grow faster than ever. than we do in other segments. Perl & Plakoff continue to outperform 33% organic growth and NatureVet 14%. The NatureVet brand is really starting to take off now with our online sales on Amazon. So we're really happy to see that. Coming back to the international turmoil, no visible effects as of yet in demand in markets or for us when it comes to any getting products. Of course, transportation costs a bit higher, but not a major i...